Keragon Founder Used Claude to Avoid Unnecessary Radiotherapy

Connor Christou describes himself as "lucky in my unluckiness." The 35-year-old founder of Keragon, a company that automates administrative operations for medical practices, discovered an 11-by-11-by-8 centimeter tumor behind his sternum while seeking treatment for blood clots. The diagnosis was a rare non-Hodgkin's lymphoma affecting roughly one in 420,000 people. What followed was an unusually data-intensive treatment journey, reported by TechCrunch, in which Claude played a recurring role.

Throughout his treatment, Christou fed "blood results, scan data, wearable output, journal entries" into the model. When his final PET scan came back ambiguous, Claude flagged a benign explanation: thymus rebound, a known phenomenon in patients under 40 recovering from this type of lymphoma. The model put roughly 90% probability on this reading. Three additional physician consultations confirmed no active disease was present, making radiotherapy unnecessary. Christou is direct about what the AI did and did not do: "It didn't replace the doctors...but it helped me ask the right questions."

Part of what makes this case notable is the underlying diagnostic landscape. According to Christou, end-of-treatment PET scans for his specific lymphoma type carry roughly a 60% false-positive rate, a number he frames pointedly: "It's 2026. Sixty percent." For rare diseases where, in Christou's words, access to comprehensive medical literature is "simply not the same as a Google search," that gap between clinical ambiguity and available information is exactly where AI can help patients prepare sharper conversations with their physicians.

The honest caveat is that Mass General Brigham's clinical lead, as quoted in the piece, described general-purpose chatbots as "frequently wrong" and noted they "have not been thoroughly evaluated" for personalized diagnoses. Christou's outcome also rested on unusual resources: 12 medical opinions gathered across his treatment, wearable health tracking, and hands-on use of frontier AI. Whether this pathway generalizes to patients without those advantages is a question the reporting does not answer.

The case for watching this space is straightforward. Rare-disease patients have always faced a literature problem: too much to read, too little time, and too few physicians who specialize in a condition affecting one in 420,000 people. If AI can reliably compress that into better-prepared clinical conversations, the value is real. What remains unsettled is whether it can be delivered safely and consistently at scale, rather than case by case.